Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: A systematic literature review

2013 ◽  
Vol 34 (4) ◽  
pp. 312-327 ◽  
Author(s):  
Konrad Bork ◽  
Isabella Steffensen ◽  
Thomas Machnig
2020 ◽  
Vol 16 (1) ◽  
Author(s):  
Donald Levy ◽  
Timothy Craig ◽  
Paul K. Keith ◽  
Girishanthy Krishnarajah ◽  
Rachel Beckerman ◽  
...  

2019 ◽  
Vol 143 (2) ◽  
pp. AB43
Author(s):  
Donald S. Levy ◽  
Paul Keith ◽  
Timothy Craig ◽  
Subhransu Prusty ◽  
Girishanthy Krishnarajah ◽  
...  

Author(s):  
Tasha S. Hellu ◽  
Samuel L. Weiss ◽  
Derek M. Smith

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurring episodes of subcutaneous and/or submucosal edema without urticaria due to an excess of bradykinin (1, 2). HAE is classified into 2 main types (1). Type I HAE is caused by deficiency of C1 esterase inhibitor, accounting for 85% of cases (1). Type II HAE occurs in only 15% of cases and is marked by normal to elevated levels of C1 esterase inhibitor but with a reduction in activity (1). An angioedema attack can range in severity depending on the location and degree of edema (2). Furthermore, patients with HAE are often diagnosed with anxiety and depression secondary to their poor quality of life (3). Thus, long-term prophylaxis of attacks can be crucial to reduce the physical and psychological implications. For long-term prophylaxis, lanadelumab, a subcutaneously delivered monoclonal antibody inhibitor of plasma kallikrein, has been proven to decrease the frequency of HAE attacks without significant side effects (4). However, data is limited, specifically regarding patients with type II HAE and patients >/= 65 years (4).


Author(s):  
Marco Cicardi ◽  
Lorenza Zingale ◽  
Andrea Zanichelli ◽  
Daniela Lambertenghi Deliliers

2021 ◽  
Vol 14 (4) ◽  
pp. 100535
Author(s):  
Anna Valerieva ◽  
Maria T. Staevska ◽  
Vesna Grivcheva-Panovska ◽  
Milos Jesenak ◽  
Kinga Viktória Kőhalmi ◽  
...  

2014 ◽  
Vol 2 (1) ◽  
pp. 77-84.e1 ◽  
Author(s):  
Jonathan A. Bernstein ◽  
Michael E. Manning ◽  
Henry Li ◽  
Martha V. White ◽  
James Baker ◽  
...  

2011 ◽  
Vol 4 ◽  
pp. S9-S21 ◽  
Author(s):  
Richard G Gower ◽  
Paula J Busse ◽  
Emel Aygören-Pürsün ◽  
Amin J Barakat ◽  
Teresa Caballero ◽  
...  

2021 ◽  
Vol 42 (4) ◽  
pp. 317-324
Author(s):  
Felix. A. Johnson ◽  
Magdalena Wirth ◽  
Zhaojun Zhu ◽  
Janina Hahn ◽  
Jens Greve ◽  
...  

Introduction: Hereditary angioedema (HAE) is a disease that leads to recurrent swelling of the skin and mucous membranes, including the upper airway tract. Apart from being deadly, these attacks can be debilitating, which leads to a poor quality of life in patients. Clinicians are occasionally confronted with patients who have recurrent attacks despite treatment with C1 esterase inhibitor concentrate or β2-receptor antagonists. The goal of this study was to investigate repeated attacks that occur 48 hours to 7 days (“cluster attacks”) after treatment, to determine why they occur and the factors that may be associated with them, and thus to prevent their occurrence. Methods: We conducted a multicenter mixed retrospective-prospective study with data acquired from all documented attacks in our patients with collective (n = 132) between 2015 and 2018. Results: Eighty-five percent (n = 132) of our total patient collective (N = 156) agreed to participate in the study. Nine percent of these patients (n = 12) had cluster attacks, with a total of 48 cluster attacks. The data procured from the patients were mixed retrospective‐prospective. Approximately 72% of all the cluster attacks were caused by exogenous stimuli (41% due to psychological stress, 29% due to physical stimuli, and 2% due to menstruation). Cluster attacks occurred in 7% of the patients who received prophylactic therapy in comparison with 12.5% of patients who received on-demand therapy. Cluster attacks comprised 48.4% of all the attacks that patients with cluster-attacks (n= 9) experienced. In addition, the patients who were underdosing their C1 esterase inhibitor treatment had cluster attacks more often. A lower “time to repeated attack” was seen in the patients who received on-demand therapy compared with those who received prophylactic therapy. Discussion: The percentage of the patients who had attacks as a result of exogenous triggers was higher in the cluster-attack group (70.5%) compared with the general HAE population (30‐42%). Repeated attacks, therefore, were strongly associated with external triggers. The patients who received prophylactic treatment and who experienced cluster attacks were highly likely to have been underdosing, which may explain the repeated attacks despite treatment. In the patients prone to cluster attacks, prophylaxis should be considered.


Author(s):  
Sufia Athar ◽  
Noureddine Korichi ◽  
Yousra Shehada Siam

Hereditary angioedema (HAE) caused by C1-esterase inhibitor deficiency is an autosomal-dominant disease caused by a mutation in the C1-inhibitor gene. It is a rare disease that is often worsened during pregnancy and childbirth. HAE, though uncommon but if untreated it may lead to maternal death.  The case report presents the successful management of a 24 years old, G2P1, with hereditary angioedema caused by C1-esterase inhibitor deficiency. This patient was managed with a multidisciplinary approach by an obstetrician, an immunologist, an anaesthesiologist and a pediatrician. She had an uneventful antenatal period, labor was induced. She had precipitate delivery and soon after delivery had a flare up of the disease. It was successfully managed with fresh frozen plasma and close observation. 


Sign in / Sign up

Export Citation Format

Share Document